A Trial Investigating the Influence of Oral Semaglutide on the Pharmacokinetics of Lisinopril and Warfarin in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

February 27, 2014

Primary Completion Date

August 20, 2014

Study Completion Date

August 20, 2014

Conditions
DiabetesHealthy
Interventions
DRUG

semaglutide

For oral administration once daily. Doses of 5 mg and 10 mg, respectively, will be given for 7 days followed by 20 mg administered on days 43-84.

DRUG

lisinopril

For oral administration. A single dose of 20 mg is administered three times either alone or conconmitantly with a perpetrator compound (days 1, 15 and 71).

DRUG

warfarin

For oral administration. A single dose of 5 mg is administered three times either alone or conconmitantly with a perpetrator compound (days 8, 22 and 78).

DRUG

placebo

A single dose of SNAC is administered conconmitantly with victim compounds (days 15 and 22).

Trial Locations (1)

14050

Novo Nordisk Investigational Site, Berlin

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY